These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29084188)

  • 21. A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study.
    Juvelekian G; El-Sorougi W; Pothirat C; Yunus F; De Guia T; Kuo HP; Basu Patnaik S; Pilipovic V
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2109-20. PubMed ID: 26491281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.
    Mahler DA; Buhl R; Lawrence D; McBryan D
    Pulm Pharmacol Ther; 2013 Jun; 26(3):348-55. PubMed ID: 23434446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
    van Noord JA; Buhl R; Laforce C; Martin C; Jones F; Dolker M; Overend T
    Thorax; 2010 Dec; 65(12):1086-91. PubMed ID: 20978028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indacaterol in the Treatment of Chronic Obstructive Pulmonary Disease: From Clinical Trials to Daily Practice.
    Incorvaia C; Ridolo E; Riario-Sforza E; Montagni M; Riario-Sforza GG
    Rev Recent Clin Trials; 2014; 9(2):96-101. PubMed ID: 24882396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies.
    Tashkin DP; Goodin T; Bowling A; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
    Respir Med; 2019 Aug; 155():113-120. PubMed ID: 31344660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
    Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indacaterol/Glycopyrronium in the Treatment of Severe Respiratory Failure: Marked Improvement of Respiratory Failure in a Few Weeks - A Case Report.
    Pistelli R; Castriotti MR; Panico L
    Respiration; 2018; 95 Suppl 1():19-21. PubMed ID: 29705782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes.
    Namba Y; Togo S; Tulafu M; Kadoya K; Nagahama KY; Taka H; Kaga N; Orimo A; Liu X; Takahashi K
    Respir Res; 2017 Mar; 18(1):46. PubMed ID: 28284212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indacaterol therapy in patients with COPD not receiving other maintenance treatment.
    Decramer M; Rossi A; Lawrence D; McBryan D
    Respir Med; 2012 Dec; 106(12):1706-14. PubMed ID: 23031496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Assessment of patient-reported outcomes by questionnaires in patients with Moderate and severe chronic obstructive pulmonary disease treated with glycopyrroniUm in the reaL lifE setTing in Hungary (AMULET)].
    Tamási L; Speer G;
    Orv Hetil; 2020 Feb; 161(8):295-305. PubMed ID: 32073290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular safety of two bronchodilators' fixed-dose combination: indacaterol and glycopyrronium.
    Kozielski J
    Pneumonol Alergol Pol; 2015; 83(2):164-70. PubMed ID: 25754060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
    Vogelmeier CF; Bateman ED; Pallante J; Alagappan VK; D'Andrea P; Chen H; Banerji D
    Lancet Respir Med; 2013 Mar; 1(1):51-60. PubMed ID: 24321804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
    Jones PW; Mahler DA; Gale R; Owen R; Kramer B
    Respir Med; 2011 Jun; 105(6):892-9. PubMed ID: 21397482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indacaterol-Glycopyrronium for COPD.
    Franssen FM; Wouters EF; Vanfleteren LE
    N Engl J Med; 2016 Sep; 375(9):898-9. PubMed ID: 27579650
    [No Abstract]   [Full Text] [Related]  

  • 36. Indacaterol-Glycopyrronium for COPD.
    Contoli M; Morelli P; Papi A
    N Engl J Med; 2016 Sep; 375(9):898. PubMed ID: 27579649
    [No Abstract]   [Full Text] [Related]  

  • 37. Indacaterol-Glycopyrronium for COPD.
    Suissa S
    N Engl J Med; 2016 Sep; 375(9):897-8. PubMed ID: 27579648
    [No Abstract]   [Full Text] [Related]  

  • 38. Indacaterol-Glycopyrronium for COPD.
    Wedzicha JA; Banerji D; Vogelmeier CF
    N Engl J Med; 2016 Sep; 375(9):899-900. PubMed ID: 27579647
    [No Abstract]   [Full Text] [Related]  

  • 39. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A; Babu KS; Morjaria JB
    Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.